Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Puma Biotechnology, Inc.

At Puma Biotechnology, our focus is on bringing innovative therapies to patients to enhance cancer care. 

We are thankful to be part of the HER2+ breast cancer community and are passionate about evaluating options that may benefit patients across the breast cancer therapy spectrum.

msh id	COM:PUMABIOTECHNOLOGY
symbol	PBYI
name	Puma Biotechnology, Inc.
homepage url	https://www.pumabiotechnology.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	185
crunchbase url	-
linkedin url	-
founders	-

market cap	146.65M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.03
growth cost of revenue	0.14
growth depreciation and amortization	0.48
growth ebitda	0.42
growth ebitda ratio	0.38
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.02
growth gross profit	0
growth gross profit ratio	-0.03

COM:PUMABIOTECHNOLOGY

Puma Biotechnology, Inc.

Last Close

2.84

21/11 21:00

Market Cap

146.65M

Beta: -

Volume Today

403.98K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	202.37M
cost of revenue	202.37M
depreciation and amortization	11.52M
ebitda	44.78M
ebitda ratio	0.19
eps	0.46
eps diluted	0.45
operating expenses	139.69M
operating income	33.27M
operating income ratio	0.14

accounts receivables	-8.37M
capital expenditure	-12.64M
cash at beginning of period	76.2M
cash at end of period	84.59M
inventory	7.08M
working capital ttm	57.99M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-